Vikas Khetan

Vikas Khetan

Auto-generated profile, based on publicly available information

Vikas Khetan

Shri Bhagwan Mahavir Vitreoretinal Services, Sankara Nethralaya, Chennai, Tamil Nadu, India

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2008 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
HDHelen Dimaras
Helen Dimaras
VKVikas Khetan
Vikas Khetan
WHWilliam Halliday
William Halliday
MOMarija Orlic-Milacic
Marija Orlic-Milacic
NPNadia L. Prigoda
Nadia L. Prigoda
BGBrenda Gallie
Brenda Gallie
Retinoblastoma clinical observations revealed the role of tumor suppressor genes in human cancer, Knudson's ‘two-hit’ model of cancer induction. We now demonstrate that loss of both RB1 tumor suppressor gene alleles initiates quiescent RB1−/− retinomas with low level genomic instability and high expression of the senescence-associated proteins p16INK4a and p130. Although retinomas can remain unchanged throughout life, highly proliferative, clonal and aneuploid retinoblastomas commonly emerge, exhibiting altered gene copy number and expression of oncogenes (MYCN, E2F3, DEK, KIF14 and MDM4) and tumor suppressor genes (CDH11, p75NTR) and reduced expression of p16INK4a and p130. We suggest that RB1 inactivation in developing retina induces genomic instability, but senescence can block transformation at the stage of retinoma. However, stable retinoma is rarely clinically observed because progressive genomic instability commonly leads to highly proliferative retinoblastoma.

1 May 2020 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
GGGlobal Retinoblastoma Study Group
Global Retinoblastoma Study Group
IFIdo Didi Fabian
Ido Didi Fabian
EAElhassan Abdallah
Elhassan Abdallah
SAShehu U. Abdullahi
Shehu U. Abdullahi
RARula A. Abdulqader
Rula A. Abdulqader
RBRichard Bowman
Richard Bowman
Retinoblastoma, the most common eye cancer of childhood, is fatal if left untreated. Prognosis of patients with retinoblastoma in high-income countries (HICs) has improved over the past 50 years, now reaching a near 100% disease-free survival rate.1-3 This is attributed to several factors, including (1) creation of specialized referral centers, (2) decoding of the genetic basis of the disease, (3) formation of screening programs, and (4) the introduction of chemotherapy.4 In HICs, retinoblastoma is a curable disease, and attention has now shifted to eye salvage5,6 and improvement of quality of life.7 In low- and middle-income countries (LMICs), where more than 80% of global retinoblastoma cases arise, the prognosis is poor, and it is assumed that this is because of delayed diagnosis and treatment.8-10 Publications from LMICs are scarce, and many countries do not report their retinoblastoma data.11 The stage of retinoblastoma at the time of diagnosis in low-income, middle-income, and high-income countries has not been surveyed globally. This information is important for policy and health care planning at national and international levels.

23 August 2010 in British Journal of Ophthalmology
Verified
Journal Article
Closed access
PDF file
SCS. Canturk
S. Canturk
IQI. Qaddoumi
I. Qaddoumi
VKV. Khetan
V. Khetan
ZMZ. Ma
Z. Ma
AFA. Furmanchuk
A. Furmanchuk
GCG. L. Chantada
G. L. Chantada
Background The survival of retinoblastoma in less-developed countries (LDCs) and the impact of socioeconomic variables on survival are not widely available in the literature. Methods A systematic review of publications from LDCs was performed. Articles were from multiple databases and written in seven languages. Results were correlated with socioeconomic indicators. Lower-income countries (LICs) and middle-income countries (MICs) were included in our analyses. Results An analysis of 164 publications including 14 800 patients from 48 LDCs was performed. Twenty-six per cent of the papers were written in languages other than English. Estimated survival in LICs was 40% (range, 23–70%); in lower MICs, 77% (range, 60–92%) and in upper MICs, 79% (range, 54–93%; p=0.001).Significant differences were also found in the occurrence of metastasis: in LICs, 32% (range, 12–45); in lower MICs, 12% (range, 3–31) and in upper MICs, 9.5% (range, 3–24; p=0.04). On multivariate analysis, physician density and human development index were significantly associated with survival and metastasis. Maternal mortality rate and per capita health expenditure were significantly associated with treatment refusal. Conclusions Important information from LDCs is not always available in English or in major databases. Indicators of socioeconomic development and maternal and infant health were related with outcome.

11 November 2010 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
GCGuillermo L Chantada
Guillermo L Chantada
IQIbrahim Qaddoumi
Ibrahim Qaddoumi
SCSerife Canturk
Serife Canturk
VKVikas Khetan
Vikas Khetan
ZMZhigui Ma
Zhigui Ma
DADavid H. Abramson
David H. Abramson

1 November 2019 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PCPatricia Chévez-Barrios
Patricia Chévez-Barrios
RERalph C. Eagle
Ralph C. Eagle
MKMark Krailo
Mark Krailo
JPJin Piao
Jin Piao
DADaniel M. Albert
Daniel M. Albert
MCMurali Chintagumpala
Murali Chintagumpala
PURPOSE: To prospectively determine the prevalence of high-risk histopathologic features (HRFs) in patients with unilateral retinoblastoma who undergo enucleation and to evaluate the role of chemotherapy in preventing recurrences. PATIENTS AND METHODS: Children newly diagnosed with enucleated unilateral retinoblastoma were enrolled prospectively. After central histopathology review, patients with specific HRFs received chemotherapy; others were observed. Primary end points were event-free survivals (EFS). RESULTS: Of the 331 patients enrolled during 2005 to 2010, 321 eligible patients had central histopathologic review. Discordance between central review and contributing institutions occurred in 23% of patients with HRFs and in 17% of patients without HRFs. Postlaminar optic nerve involvement was present in 53 patients; 42 had massive posterior uveal invasion (≥ 3 mm); 15 had concomitant peripapillary 3 mm or greater choroid and postlaminar optic nerve involvement; and 15 had focal (< 3 mm) choroidal concomitant with lamina or prelamina optic nerve involvement. Two-year EFS for patients with HRFs requiring adjuvant chemotherapy was 0.96 (95% CI, 0.89 to 0.98), and 2-year EFS for patients without HRFs for which observation was indicated was 0.99 (95% CI, 0.96 to 1.0). The 2-year EFS for all patients was 0.98 (95% CI, 0.96 to 0.99). CONCLUSION: Adequate handling and interpretation of histopathology of eyes with retinoblastoma is necessary to assign metastatic risk. Concomitant less than 3 mm choroidal and any prelaminar/laminar optic nerve invasion show no recurrence and may warrant no adjuvant chemotherapy. In contrast, concomitant greater than 3 mm peripapillary choroidal invasion and 1.5 mm or greater of postlaminar optic nerve invasion have the poorest outcomes, supporting the need for a more intensive adjuvant chemotherapy regimen for this subgroup. Strict criteria for adjuvant therapy may improve outcomes of children who undergo enucleation at diagnosis and may avoid unnecessary adjuvant chemotherapy for those who are not at risk for recurrence.

1 November 2018 in Eye
Verified
Journal Article
Closed access
PDF file
MJMukesh Jain
Mukesh Jain
DRDuangnate Rojanaporn
Duangnate Rojanaporn
BCBhavna Chawla
Bhavna Chawla
GSGangadhar Sundar
Gangadhar Sundar
LGLingam Gopal
Lingam Gopal
VKVikas Khetan
Vikas Khetan